Schneeberger Daniel 的 Form 4 申報
NextCure, Inc.（NXTC），2026/8/3 申報
- 申報編號
- 0001940272-26-000013
- 申報時間
- 2026/8/3 17:53 ET
- 交易日
- 2026/7/30-7/31
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 9 筆非衍生性交易。公開市場買進合計 $162.4 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Schneeberger DanielCIK 0001861120 | 持股 10% 以上大股東 |
| ADAR1 Capital Management, LLCCIK 0001940272 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/7/30 | Common Stock | P買進取得 | +50,000 | $4.97F1 | +$248,615 | 443,266 | 間接 | |
| 2026/7/30 | Common Stock | P買進取得 | +20,000 | $5.00 | +$100,000 | 463,266 | 間接 | |
| 2026/7/30 | Common Stock | P買進取得 | +20,000 | $5.00 | +$100,000 | 483,266 | 間接 | |
| 2026/7/30 | Common Stock | P買進取得 | +25,000 | $4.81F2 | +$120,337.5 | 508,266 | 間接 | |
| 2026/7/30 | Common Stock | P買進取得 | +100,000 | $4.90 | +$490,000 | 608,266 | 間接 | |
| 2026/7/30 | Common Stock | P買進取得 | +77,850 | $4.96F3 | +$385,793.46 | 686,116 | 間接 | |
| 2026/7/31 | Common Stock | P買進取得 | +3,300 | $4.98F4 | +$16,420.14 | 689,416 | 間接 | |
| 2026/7/31 | Common Stock | P買進取得 | +25,000 | $4.98F5 | +$124,540 | 714,416 | 間接 | |
| 2026/7/31 | Common Stock | P買進取得 | +8,003 | $4.80 | +$38,414.4 | 722,419 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F2
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.8100 to $4.8450, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.7563 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9100 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9740 to $4.9824, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。